Article Versions Notes

Ito N, Tajika M, Tanaka T, Yamada K, Takagi A, Onishi S, Abe T, Higaki E, Fujieda H, Inaba Y, et al. Skeletal Muscle Quality and Quantity Affect Prognosis after Neoadjuvant Chemotherapy with a Triple Regimen of Docetaxel/Cisplatin/5-FU in Patients with Esophageal Cancer. Journal of Clinical Medicine. 2023; 12(21):6738. https://doi.org/10.3390/jcm12216738

Ito, Nobuhito, Masahiro Tajika, Tsutomu Tanaka, Keisaku Yamada, Akihiro Takagi, Sachiyo Onishi, Tetsuya Abe, Eiji Higaki, Hironori Fujieda, Yoshitaka Inaba, and et al. 2023. "Skeletal Muscle Quality and Quantity Affect Prognosis after Neoadjuvant Chemotherapy with a Triple Regimen of Docetaxel/Cisplatin/5-FU in Patients with Esophageal Cancer" Journal of Clinical Medicine 12, no. 21: 6738. https://doi.org/10.3390/jcm12216738

Ito, N., Tajika, M., Tanaka, T., Yamada, K., Takagi, A., Onishi, S., Abe, T., Higaki, E., Fujieda, H., Inaba, Y., Muro, K., Kawashima, H., & Niwa, Y. (2023). Skeletal Muscle Quality and Quantity Affect Prognosis after Neoadjuvant Chemotherapy with a Triple Regimen of Docetaxel/Cisplatin/5-FU in Patients with Esophageal Cancer. Journal of Clinical Medicine, 12(21), 6738. https://doi.org/10.3390/jcm12216738